Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia

Daniel T. Stein, Sridevi Devaraj, David Balis, Beverley Adams-Huet, Ishwarlal Jialal

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Clinical trials with statins have demonstrated significant reductions in cardiovascular events. Remnant lipoproteins are independent predictors of cardiovascular events. Because of the paucity of data on the effect of statins on remnant lipoproteins, we tested the effect of pravastatin, simvastatin, and atorvastatin on remnant lipoprotein cholesterol (RLP-C) levels in a randomized crossover study in patients with combined hyperlipidemia. After a 6-week diet phase, patients (n=22) were randomized to pravastatin (40 mg/d), simvastatin (20 mg/d), or atorvastatin (10 mg/d) for 6 weeks, with a 3-week washout between each drug. All 3 drugs significantly decreased total and low density lipoprotein (LDL) cholesterol (P<0.001). Mean reduction in LDL cholesterol with pravastatin, simvastatin, and atorvastatin was 21%, 29%, and 32%, respectively. None of the drugs affected high density lipoprotein cholesterol levels. Median levels of triglycerides were significantly reduced with simvastatin (26%, P=0.001) and atorvastatin (24%, P=0.0001) but not with pravastatin (9%, P=0.18). Non-high density lipoprotein cholesterol decreased significantly with all 3 statins (20%, 29%, and 32% with pravastatin, simvastatin, and atorvastatin, respectively; P<0.001). Median RLP-C levels were significantly reduced with simvastatin (6%, P<0.05) and atorvastatin (25.9%, P<0.001) but not with pravastatin (2.9%, P=0.58). Thus, atorvastatin and simvastatin, in addition to reducing LDL cholesterol and triglyceride levels, significantly reduced RLP-C levels. This could be another potential mechanism to explain their cardiovascular benefits.

Original languageEnglish (US)
Pages (from-to)2026-2031
Number of pages6
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume21
Issue number12
StatePublished - 2001
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin
Pravastatin
Hyperlipidemias
LDL Cholesterol
Therapeutics
Lipoproteins
Pharmaceutical Preparations
Atorvastatin Calcium
lipoprotein cholesterol
Cross-Over Studies
HDL Cholesterol
Triglycerides
Clinical Trials
Diet

Keywords

  • Non-HDL cholesterol
  • Remnants
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. / Stein, Daniel T.; Devaraj, Sridevi; Balis, David; Adams-Huet, Beverley; Jialal, Ishwarlal.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 21, No. 12, 2001, p. 2026-2031.

Research output: Contribution to journalArticle

Stein, Daniel T. ; Devaraj, Sridevi ; Balis, David ; Adams-Huet, Beverley ; Jialal, Ishwarlal. / Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2001 ; Vol. 21, No. 12. pp. 2026-2031.
@article{c2ea40d57e6c481790dd92d023caf61d,
title = "Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia",
abstract = "Clinical trials with statins have demonstrated significant reductions in cardiovascular events. Remnant lipoproteins are independent predictors of cardiovascular events. Because of the paucity of data on the effect of statins on remnant lipoproteins, we tested the effect of pravastatin, simvastatin, and atorvastatin on remnant lipoprotein cholesterol (RLP-C) levels in a randomized crossover study in patients with combined hyperlipidemia. After a 6-week diet phase, patients (n=22) were randomized to pravastatin (40 mg/d), simvastatin (20 mg/d), or atorvastatin (10 mg/d) for 6 weeks, with a 3-week washout between each drug. All 3 drugs significantly decreased total and low density lipoprotein (LDL) cholesterol (P<0.001). Mean reduction in LDL cholesterol with pravastatin, simvastatin, and atorvastatin was 21{\%}, 29{\%}, and 32{\%}, respectively. None of the drugs affected high density lipoprotein cholesterol levels. Median levels of triglycerides were significantly reduced with simvastatin (26{\%}, P=0.001) and atorvastatin (24{\%}, P=0.0001) but not with pravastatin (9{\%}, P=0.18). Non-high density lipoprotein cholesterol decreased significantly with all 3 statins (20{\%}, 29{\%}, and 32{\%} with pravastatin, simvastatin, and atorvastatin, respectively; P<0.001). Median RLP-C levels were significantly reduced with simvastatin (6{\%}, P<0.05) and atorvastatin (25.9{\%}, P<0.001) but not with pravastatin (2.9{\%}, P=0.58). Thus, atorvastatin and simvastatin, in addition to reducing LDL cholesterol and triglyceride levels, significantly reduced RLP-C levels. This could be another potential mechanism to explain their cardiovascular benefits.",
keywords = "Non-HDL cholesterol, Remnants, Statins",
author = "Stein, {Daniel T.} and Sridevi Devaraj and David Balis and Beverley Adams-Huet and Ishwarlal Jialal",
year = "2001",
language = "English (US)",
volume = "21",
pages = "2026--2031",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia

AU - Stein, Daniel T.

AU - Devaraj, Sridevi

AU - Balis, David

AU - Adams-Huet, Beverley

AU - Jialal, Ishwarlal

PY - 2001

Y1 - 2001

N2 - Clinical trials with statins have demonstrated significant reductions in cardiovascular events. Remnant lipoproteins are independent predictors of cardiovascular events. Because of the paucity of data on the effect of statins on remnant lipoproteins, we tested the effect of pravastatin, simvastatin, and atorvastatin on remnant lipoprotein cholesterol (RLP-C) levels in a randomized crossover study in patients with combined hyperlipidemia. After a 6-week diet phase, patients (n=22) were randomized to pravastatin (40 mg/d), simvastatin (20 mg/d), or atorvastatin (10 mg/d) for 6 weeks, with a 3-week washout between each drug. All 3 drugs significantly decreased total and low density lipoprotein (LDL) cholesterol (P<0.001). Mean reduction in LDL cholesterol with pravastatin, simvastatin, and atorvastatin was 21%, 29%, and 32%, respectively. None of the drugs affected high density lipoprotein cholesterol levels. Median levels of triglycerides were significantly reduced with simvastatin (26%, P=0.001) and atorvastatin (24%, P=0.0001) but not with pravastatin (9%, P=0.18). Non-high density lipoprotein cholesterol decreased significantly with all 3 statins (20%, 29%, and 32% with pravastatin, simvastatin, and atorvastatin, respectively; P<0.001). Median RLP-C levels were significantly reduced with simvastatin (6%, P<0.05) and atorvastatin (25.9%, P<0.001) but not with pravastatin (2.9%, P=0.58). Thus, atorvastatin and simvastatin, in addition to reducing LDL cholesterol and triglyceride levels, significantly reduced RLP-C levels. This could be another potential mechanism to explain their cardiovascular benefits.

AB - Clinical trials with statins have demonstrated significant reductions in cardiovascular events. Remnant lipoproteins are independent predictors of cardiovascular events. Because of the paucity of data on the effect of statins on remnant lipoproteins, we tested the effect of pravastatin, simvastatin, and atorvastatin on remnant lipoprotein cholesterol (RLP-C) levels in a randomized crossover study in patients with combined hyperlipidemia. After a 6-week diet phase, patients (n=22) were randomized to pravastatin (40 mg/d), simvastatin (20 mg/d), or atorvastatin (10 mg/d) for 6 weeks, with a 3-week washout between each drug. All 3 drugs significantly decreased total and low density lipoprotein (LDL) cholesterol (P<0.001). Mean reduction in LDL cholesterol with pravastatin, simvastatin, and atorvastatin was 21%, 29%, and 32%, respectively. None of the drugs affected high density lipoprotein cholesterol levels. Median levels of triglycerides were significantly reduced with simvastatin (26%, P=0.001) and atorvastatin (24%, P=0.0001) but not with pravastatin (9%, P=0.18). Non-high density lipoprotein cholesterol decreased significantly with all 3 statins (20%, 29%, and 32% with pravastatin, simvastatin, and atorvastatin, respectively; P<0.001). Median RLP-C levels were significantly reduced with simvastatin (6%, P<0.05) and atorvastatin (25.9%, P<0.001) but not with pravastatin (2.9%, P=0.58). Thus, atorvastatin and simvastatin, in addition to reducing LDL cholesterol and triglyceride levels, significantly reduced RLP-C levels. This could be another potential mechanism to explain their cardiovascular benefits.

KW - Non-HDL cholesterol

KW - Remnants

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=0035569936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035569936&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 2026

EP - 2031

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 12

ER -